Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tonge

Showing results (751-760 of 775) with videos related to

Pageof 78
Sort By:
Nature Communications|September 16, 2024
Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidosesPanagiotis Douvaras, Diego F Buenaventura, Bruce Sun, et al.
Cell Stem Cell|April 4, 2025
A call to action for deciphering genetic variants in human pluripotent stem cells for cell therapyNissim Benvenisty, Jonathan S Draper, Paul J Gokhale, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia CellsStuart Jones, Jonathan Ahmet, Kelly Ayton, et al.
Nature Communications|December 11, 2014
An epigenomic roadmap to induced pluripotency reveals DNA methylation as a reprogramming modulatorDong-Sung Lee, Jong-Yeon Shin, Peter D Tonge, et al.
BMC Genomics|March 24, 2025
Genomic-transcriptomic analysis identifies the Syrian hamster as a superior animal model for human diseasesChuchu Wang, Zhenguo Cheng, Jinxin Miao, et al.
Journal of Medicinal Chemistry|April 5, 2017
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start PointRichard A Ward, Paul Bethel, Calum Cook, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Targeted lung cancer screening selects individuals at high risk of cardiovascular diseaseH Balata, S Blandin Knight, P Barber, et al.
Nature Communications|December 11, 2014
Small RNA changes en route to distinct cellular states of induced pluripotencyJennifer L Clancy, Hardip R Patel, Samer M I Hussein, et al.
Nature Genetics|October 11, 2016
The genomic landscape of schwannomaSameer Agnihotri, Shahrzad Jalali, Mark R Wilson, et al.
Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.
Pageof 78

Showing results (751-760 of 775) with videos related to

Sort By:
Pageof 78
Nature Communications|September 16, 2024
Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidosesPanagiotis Douvaras, Diego F Buenaventura, Bruce Sun, et al.
Cell Stem Cell|April 4, 2025
A call to action for deciphering genetic variants in human pluripotent stem cells for cell therapyNissim Benvenisty, Jonathan S Draper, Paul J Gokhale, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia CellsStuart Jones, Jonathan Ahmet, Kelly Ayton, et al.
Nature Communications|December 11, 2014
An epigenomic roadmap to induced pluripotency reveals DNA methylation as a reprogramming modulatorDong-Sung Lee, Jong-Yeon Shin, Peter D Tonge, et al.
BMC Genomics|March 24, 2025
Genomic-transcriptomic analysis identifies the Syrian hamster as a superior animal model for human diseasesChuchu Wang, Zhenguo Cheng, Jinxin Miao, et al.
Journal of Medicinal Chemistry|April 5, 2017
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start PointRichard A Ward, Paul Bethel, Calum Cook, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Targeted lung cancer screening selects individuals at high risk of cardiovascular diseaseH Balata, S Blandin Knight, P Barber, et al.
Nature Communications|December 11, 2014
Small RNA changes en route to distinct cellular states of induced pluripotencyJennifer L Clancy, Hardip R Patel, Samer M I Hussein, et al.
Nature Genetics|October 11, 2016
The genomic landscape of schwannomaSameer Agnihotri, Shahrzad Jalali, Mark R Wilson, et al.
Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.
Pageof 78